Contrasting Kiromic BioPharma (NASDAQ:KRBP) and Aligos Therapeutics (NASDAQ:ALGS)

Kiromic BioPharma (NASDAQ:KRBP) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility and Risk

Kiromic BioPharma has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500.

Institutional & Insider Ownership

10.9% of Kiromic BioPharma shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 20.6% of Kiromic BioPharma shares are owned by insiders. Comparatively, 8.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Kiromic BioPharma and Aligos Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	-$26.90 million	($3.50)	-0.45
Aligos Therapeutics	$6.00 million	10.55	-$87.68 million	($13.32)	-1.32

Kiromic BioPharma has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Kiromic BioPharma and Aligos Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	0.00
Aligos Therapeutics	0	0	1	0	3.00

Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 325.29%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Kiromic BioPharma.

Profitability

This table compares Kiromic BioPharma and Aligos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	-277.46%
Aligos Therapeutics	-1,283.19%	-114.34%	-64.58%

Summary

Aligos Therapeutics beats Kiromic BioPharma on 7 of the 13 factors compared between the two stocks.

About Kiromic BioPharma

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.